Design, synthesis of new gatifloxacin derivatives as antibacterial activity

Abstract

Infectious disease-causing organisms are known as pathogens. They consist of viruses, fungi, bacteria, and parasites. Quinolones function by preventing either bacterial gyrase or topoisomerase IV from acting. A series of oxadiazole derivatives was added to the antibacterial fluoroquinolone gatifloxacin to increase bulkiness at the C7 piperazine ring. The present study employed 2D FT-IR and 1H-NMR spectroscopy, as well as physical and chemical parameters like melting points, to characterize the synthesized compounds. The antibacterial activity of the compounds was tested against Gram-negative bacteria, specifically Aeruginosa pseudomonas. The tested compounds demonstrated no inhibition of the bacteria used in the research. The final synthetic chemicals' affinity for the topoisomerase IV enzyme was demonstrated by docking research. The results of this investigation demonstrated that the gatifloxacin-derived compounds had no effect on the activity of the bacteria employed in the investigation.